Evaluation of bone turnover after bisphosphonate withdrawal and its influence on implant osseointegration: an in vivo study in rats
Carregando...
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2019
Editora
SPRINGER HEIDELBERG
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
FRIZZERA, Fausto
VERZOLA, Mario Henrique Arruda
MOLON, Rafael Scaf de
OLIVEIRA, Guilherme Jose Pimentel Lopes de
GIRO, Gabriela
SPOLIDORIO, Luis Carlos
TETRADIS, Sotirios
CIRELLI, Joni Augusto
ORRICO, Silvana Regina Peres
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICAL ORAL INVESTIGATIONS, v.23, n.4, p.1733-1744, 2019
Resumo
ObjectivesThe aim of this study was to investigate bone turnover alterations after alendronate (ALD) withdrawal and its influence on dental implants osseointegration.Materials and methodsSeventy female Wistar rats were randomly divided in 2 groups that received on day 0 either placebo (control groupCTL; n=10) or 1mg/kg sodium alendronate (ALD; n=60) once a week for 4months. At day 120, ALD treatment was suspended for 50 animals. Then, a titanium implant was placed in the left tibia of each rat that were randomly allocated in five subgroups of ten animals each, according to the period of evaluation: day 0 (INT-0), day 7 (INT-7), day 14 (INT-14), day 28 (INT-28), and day 45 (INT-45) after ALD withdrawal. CTL group and a group that received ALD until the end of the experimental period (non-interrupted groupnon-INT; n=10) underwent implant placement on day 120. Animals were euthanized 28days after implant surgery. Bone mineral density (BMD) of femur and lumbar vertebrae were evaluated by DXA, biochemical markers of bone turnover were analyzed by ELISA, and bone histomorphometry was performed to measure bone-to-implant contact (BIC) and bone area fraction occupancy (BAFO).ResultsAll groups receiving ALD showed higher BMD values when compared to CTL group, which were maintained after its withdrawal. Decreased concentrations in all bone turnover markers were observed in the non-INT group, and in the groups in which ALD was discontinued compared to the CTL group. The non-INT group showed lower %BIC and notably changes in bone quality, which was persistent after drug withdrawal.ConclusionCollectively, the findings of this study demonstrated that ALD therapy decreased bone turnover and impaired bone quality and quantity around dental implants, and that its discontinuation did not reverse these findings.Clinical relevanceThe severe suppression of bone turnover caused by the prolonged use of ALD may alter the capacity of bone tissue to integrate with the implant threads impairing the osseointegration process.
Palavras-chave
Bisphosphonate, Alendronate, Rats, Osteoclasts, Dental implants, Osseointegration
Referências
- Abraham A, 2013, CLIN OBSTET GYNECOL, V56, P722, DOI 10.1097/GRF.0b013e3182a8ae55
- Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
- Bagger YZ, 2003, BONE, V33, P301, DOI 10.1016/S8756-3282(03)00112-1
- Bedogni A, 2010, J ORAL MAXIL SURG, V68, P1662, DOI 10.1016/j.joms.2010.02.037
- Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600-0501.2003.00972.x
- Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
- Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
- Black DM, 2006, JAMA-J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
- Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
- Carvalho MD, 2006, J PERIODONTOL, V77, P599, DOI 10.1902/jop.2006.050190
- Chacon GE, 2006, J ORAL MAXIL SURG, V64, P1005, DOI 10.1016/j.joms.2006.01.007
- Chen JT, 1996, J BONE MINER RES, V11, P1784
- da Silva AG, 2011, ARQ BRAS ENDOCRINOL, V55, P272, DOI 10.1590/S0004-27302011000400006
- de Molon RS, 2016, J BONE MINER RES, V31, P1596, DOI 10.1002/jbmr.2827
- de Molon RS, 2015, J BONE MINER RES, V30, P1627, DOI 10.1002/jbmr.2490
- de Molon RS, 2014, BONE, V68, P11, DOI 10.1016/j.bone.2014.07.027
- de Molon RS, 2013, CLIN ORAL IMPLAN RES, V24, P831, DOI 10.1111/j.1600-0501.2012.02467.x
- dos Santos PL, 2016, J PERIODONTAL IMPLAN, V46, P176, DOI 10.5051/jpis.2016.46.3.176
- Duarte PM, 2005, J PERIODONTOL, V76, P107, DOI 10.1902/jop.2005.76.1.107
- Duarte Poliana Mendes, 2003, Implant Dent, V12, P340
- Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
- Fuchs RK, 2008, J BONE MINER RES, V23, P1689, DOI 10.1359/JBMR.080501
- Giro G, 2008, ORAL SURG ORAL MED O, V105, P162, DOI 10.1016/j.tripleo.2007.06.010
- Giro G, 2007, J PERIODONTOL, V78, P1316, DOI 10.1902/jop.2007.060390
- Giro G, 2011, CLIN ORAL IMPLAN RES, V22, P259, DOI 10.1111/j.1600-0501.2010.01989.x
- Grey A, 2010, J BONE MINER RES, V25, P2251, DOI 10.1002/jbmr.103
- Guimaraes MB, 2015, INT J ORAL MAX SURG, V44, P1423, DOI 10.1016/j.ijom.2015.05.013
- Manzano-Moreno FJ, 2015, CLIN ORAL INVEST, V19, P895, DOI 10.1007/s00784-014-1309-z
- Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010
- Kim YJ, 2018, INT J ORAL MAX IMPL, V33, P512, DOI 10.11607/jomi.5959
- Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
- Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
- Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
- Mardas N, 2011, CLIN ORAL IMPLAN RES, V22, P406, DOI 10.1111/j.1600-0501.2010.02094.x
- Narai S, 2003, INT J ORAL MAX IMPL, V18, P218
- Nociti FH, 2002, INT J ORAL MAX IMPL, V17, P786
- Pan JL, 2000, J ORAL MAXIL SURG, V58, P877, DOI 10.1053/joms.2000.8212
- Queiroz TP, 2017, CLIN ORAL INVEST, V21, P685, DOI 10.1007/s00784-016-1936-7
- Russell G, 2001, Novartis Found Symp, V232, P251
- Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198-007-0540-8
- Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
- Shahnazari M, 2011, J BONE MINER RES, V26, P569, DOI 10.1002/jbmr.249
- Shirota T, 2003, J ORAL MAXIL SURG, V61, P471, DOI 10.1053/joms.2003.50093
- Soundia A, 2016, BONE, V90, P133, DOI 10.1016/j.bone.2016.06.011
- Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
- Tamura Y, 2001, J BONE MINER RES, V16, P541, DOI 10.1359/jbmr.2001.16.3.541
- Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
- Tokugawa Y, 2003, INT J ORAL MAX IMPL, V18, P66
- Tolia M, 2014, ANTICANCER RES, V34, P23
- Verzola MHA, 2015, CLIN ORAL IMPLAN RES, V26, P1466, DOI 10.1111/clr.12492
- Vidigal G M Jr, 1999, Implant Dent, V8, P295, DOI 10.1097/00008505-199903000-00015
- Viera-Negron Yeritxa E, 2008, J Oral Implantol, V34, P76, DOI 10.1563/1548-1336(2008)34[76:EOOAAO]2.0.CO;2
- Vohra F, 2014, ARCH ORAL BIOL, V59, P912, DOI 10.1016/j.archoralbio.2014.05.016
- Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
- Wasnich Richard D, 2004, Menopause, V11, P622
- Wolf G, 1996, NUTR REV, V54, P332
- Yamazaki M, 1999, ORAL SURG ORAL MED O, V87, P411, DOI 10.1016/S1079-2104(99)70239-8
- Yildiz A, 2010, J ORAL MAXIL SURG, V68, P515, DOI 10.1016/j.joms.2009.07.066
- Yip JK, 2012, J CLIN PERIODONTOL, V39, P408, DOI 10.1111/j.1600-051X.2012.01854.x
- Yuan K, 2012, IMPLANT DENT, V21, P3, DOI 10.1097/ID.0b013e3182425c62
- Zagury R, 2007, IMPLANT DENT, V16, P290, DOI 10.1097/ID.0b013e3180e9d9ed